Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States

被引:5
|
作者
Zhou, Zhou [1 ]
Zhou, Zheng-Yi [2 ]
Kelkar, Sneha S. [1 ]
Sikirica, Vanja [3 ]
Xie, Jipan [4 ]
Grebla, Regina [3 ]
机构
[1] Anal Grp Inc, 111 Huntington Ave,Floor 14, Boston, MA 02199 USA
[2] Anal Grp Inc, New York, NY USA
[3] Shire, Chesterbrook, PA USA
[4] Anal Grp Inc, Los Angeles, CA USA
关键词
Attention deficit/hyperactivity disorder; claims analysis; combination therapy; long-acting; short-acting; stimulant; DEFICIT HYPERACTIVITY DISORDER; OROS METHYLPHENIDATE; IMMEDIATE-RELEASE; ADHD; STIMULANTS; DIAGNOSIS; PREVALENCE; MANAGEMENT; ADHERENCE; PATTERNS;
D O I
10.1080/03007995.2017.1411792
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine real-world prescription medication usage among commercially-insured adults with attention deficit/hyperactivity disorder (ADHD) in the US. Methods: Adults with ADHD who received >1 ADHD medication during 2013 were identified from a large US claims database. Combination therapy was defined as an overlap of >= 30 days between the index (first treatment >= 30 days in 2013) and another medication(s). Patients were classified into six groups: long-acting (LA) monotherapy, short-acting (SA) monotherapy, LA+LA, SA+SA, LA+SA, and >2 therapies. Analyses compared baseline characteristics by regimen, ranked combination regimens, and estimated daily average consumption (DACON) for monotherapy users. Results: Of 206,443 adults with ADHD (mean age = 32.9 years; 51.6% female), 56.9% used LA monotherapy, 30.7% SA monotherapy, and 12.5% used combination therapies (LA+SA: 10.3%; LA+LA: 1.3%; SA+SA: 0.4%; >2 therapies: 0.5%). Extended-release mixed amphetamine salts (MAS-XR, 39.2%) and lisdexamfetamine (LDX, 31.5%) were the most common LA monotherapies. Nearly all SA monotherapy patients received immediate-release mixed amphetamine salts (MAS-IR; 81.7%). The top three therapies among combination categories were: (a) LA+LA: branded MAS-XR+generic MAS-XR (13.7%), LDX+eneric MAS-XR (10.8%), LDX+guanfacine ER (10.7%); (b) SA+SA: generic MAS-IR+clonidine IR (33.5%), generic MAS-IR+generic MPH SA (17.9%), branded MAS-IR+generic MAS-IR (11.1%); (c) LA+SA: generic MAS-XR+/-IR (39.2%), LDX+generic MAS-IR (16.7%), LA+SA generic MPH (12.6%). Among monotherapy users, DACON was 1.2 +/- 0.6 (LA) and 2.1 +/- 0.9 (SA) tablets. Conclusions: There is significant treatment heterogeneity among US adults with ADHD. A sizable proportion of patients received monotherapies at above the recommended dosages or combination therapies, suggesting existing single-tablet regimens may not meet patients' needs.
引用
收藏
页码:585 / 592
页数:8
相关论文
共 50 条
  • [21] Attention deficit hyperactivity disorder medications and bone mineral density of adults in the United States
    Lawson, Michael Jeremy
    Beltran, Thomas A.
    Padilla, Carla R.
    Berry-Caban, Cristobal S.
    Choi, Y. Sammy
    BONE REPORTS, 2022, 16
  • [22] Attention deficit hyperactivity disorder: Comorbidity and medication use.
    Kube, DA
    Petersen, MC
    Johnson, J
    Palmer, FB
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 105A - 105A
  • [23] RATE OF HOSPITALIZATIONS AMONG PATIENTS WITH SYSTOLIC HEART FAILURE IN A COMMERCIALLY-INSURED UNITED STATES POPULATION
    Song, X.
    Wilson, K.
    Zhang, K.
    Lei, L.
    Monsalvo, M. L.
    Kim, J.
    Cong, Z.
    VALUE IN HEALTH, 2014, 17 (03) : A118 - A119
  • [24] The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States
    Durden, Emily
    Walker, David
    Gray, Stephani
    Fowler, Robert
    Juneau, Paul
    Gooch, Katherine
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2018, 60 (09) : 847 - 852
  • [25] Attention Deficit/Hyperactivity Disorder among Adults in the United StatesTrend in Diagnosis and Use of Pharmacotherapy
    David Alexander Sclar
    Linda M. Robison
    Leigh V. Castillo
    Kurt A. Bowen
    Jennifer M. Schmidt
    Ambartsum M. Oganov
    Pharmaceutical Medicine, 2012, 26 (2) : 97 - 101
  • [26] ECONOMIC BURDEN OF UNCONTROLLED ATTENTION DEFICIT HYPERACTIVITY DISORDER IN THE US: A RETROSPECTIVE ANALYSIS OF DATABASE CLAIMS FROM A COMMERCIALLY INSURED POPULATION
    Pliszka, S. R.
    Rajagopalan, K.
    Davis, B. M.
    Montejano, L. B.
    Loebel, A.
    VALUE IN HEALTH, 2017, 20 (05) : A295 - A295
  • [27] Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder
    Guevara, J
    Lozano, P
    Wickizer, T
    Mell, L
    Gephart, H
    PEDIATRICS, 2002, 109 (05) : 733 - 739
  • [28] Attention deficit hyperactivity disorder in adults
    Cubbin, S
    Leahy, A
    BRITISH JOURNAL OF PSYCHIATRY, 1998, 172 : 366 - 366
  • [29] Attention deficit hyperactivity disorder in adults
    Sachdev, P
    PSYCHOLOGICAL MEDICINE, 1999, 29 (03) : 507 - 514
  • [30] Attention deficit/hyperactivity disorder in adults
    Moss, Shannon B.
    Nair, Rajasree
    Vallarino, Anthony
    Wang, Scott
    PRIMARY CARE, 2007, 34 (03): : 445 - +